Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.35
WAG's Cash to Debt is ranked higher than
58% of the 484 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.83 vs. WAG: 0.35 )
WAG' s 10-Year Cash to Debt Range
Min: 0.03   Max: No Debt
Current: 0.35

Equity to Asset 0.56
WAG's Equity to Asset is ranked higher than
78% of the 482 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.46 vs. WAG: 0.56 )
WAG' s 10-Year Equity to Asset Range
Min: 0.52   Max: 0.64
Current: 0.56

0.52
0.64
F-Score: 5
Z-Score: 5.59
M-Score: -2.45
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 5.46
WAG's Operating margin (%) is ranked higher than
84% of the 486 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 3.80 vs. WAG: 5.46 )
WAG' s 10-Year Operating margin (%) Range
Min: 4.84   Max: 6.05
Current: 5.46

4.84
6.05
Net-margin (%) 3.39
WAG's Net-margin (%) is ranked higher than
83% of the 486 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.37 vs. WAG: 3.39 )
WAG' s 10-Year Net-margin (%) Range
Min: 2.97   Max: 3.8
Current: 3.39

2.97
3.8
ROE (%) 12.59
WAG's ROE (%) is ranked higher than
83% of the 477 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 9.99 vs. WAG: 12.59 )
WAG' s 10-Year ROE (%) Range
Min: 11.66   Max: 18.39
Current: 12.59

11.66
18.39
ROA (%) 6.91
WAG's ROA (%) is ranked higher than
87% of the 485 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.42 vs. WAG: 6.91 )
WAG' s 10-Year ROA (%) Range
Min: 6.36   Max: 10.94
Current: 6.91

6.36
10.94
ROC (Joel Greenblatt) (%) 28.99
WAG's ROC (Joel Greenblatt) (%) is ranked higher than
85% of the 485 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 20.02 vs. WAG: 28.99 )
WAG' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 22.73   Max: 30.69
Current: 28.99

22.73
30.69
Revenue Growth (%) 3.50
WAG's Revenue Growth (%) is ranked higher than
71% of the 330 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.90 vs. WAG: 3.50 )
WAG' s 10-Year Revenue Growth (%) Range
Min: 3.5   Max: 16.5
Current: 3.5

3.5
16.5
EBITDA Growth (%) 6.40
WAG's EBITDA Growth (%) is ranked higher than
80% of the 298 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 5.00 vs. WAG: 6.40 )
WAG' s 10-Year EBITDA Growth (%) Range
Min: 6.1   Max: 17.9
Current: 6.4

6.1
17.9
EPS Growth (%) 6.50
WAG's EPS Growth (%) is ranked higher than
80% of the 297 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.60 vs. WAG: 6.50 )
WAG' s 10-Year EPS Growth (%) Range
Min: 1.5   Max: 20
Current: 6.5

1.5
20
» WAG's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

WAG Guru Trades in Q2 2013

Joel Greenblatt 10,268 sh (New)
Larry Robbins 7,575,826 sh (+136.56%)
Jeremy Grantham 2,840,086 sh (+115.81%)
Manning & Napier Advisors, Inc 92,665 sh (+75.01%)
Vanguard Health Care Fund 12,465,900 sh (+6.82%)
Mario Gabelli 207,749 sh (+3.95%)
First Pacific Advisors 2,297,300 sh (+0.89%)
Dodge & Cox 6,469 sh (unchged)
Steven Romick 2,175,000 sh (unchged)
John Rogers 164,450 sh (unchged)
Meridian Funds 15,400 sh (unchged)
Paul Tudor Jones Sold Out
Tom Russo Sold Out
Tom Gayner 2,147,800 sh (-0.17%)
Bill Frels 17,013 sh (-2.02%)
John Buckingham 152,877 sh (-6.56%)
Ken Fisher 4,859 sh (-7.16%)
RS Investment Management 50,400 sh (-9.94%)
Pioneer Investments 2,353,162 sh (-10.15%)
James Barrow 8,648,163 sh (-16.3%)
Chuck Royce 51,700 sh (-44.11%)
John Hussman 202,500 sh (-62.36%)
Steven Cohen 63,732 sh (-80.04%)
» More
Q3 2013

WAG Guru Trades in Q3 2013

Paul Tudor Jones 100,000 sh (New)
Jim Simons 1,451,800 sh (New)
Louis Moore Bacon 10,000 sh (New)
George Soros 500,000 sh (New)
John Hussman 296,500 sh (+46.42%)
Jeremy Grantham 3,640,147 sh (+28.17%)
Ken Fisher 5,755 sh (+18.44%)
Steven Cohen 73,290 sh (+15%)
Manning & Napier Advisors, Inc 97,616 sh (+5.34%)
Tom Gayner 2,149,200 sh (+0.07%)
Steven Romick 2,175,000 sh (unchged)
Vanguard Health Care Fund 12,465,900 sh (unchged)
Caxton Associates 800,000 sh (unchged)
Joel Greenblatt Sold Out
John Buckingham 152,337 sh (-0.35%)
First Pacific Advisors 2,288,500 sh (-0.38%)
Pioneer Investments 2,324,514 sh (-1.22%)
Bill Frels 16,788 sh (-1.32%)
Larry Robbins 7,442,926 sh (-1.75%)
RS Investment Management 49,300 sh (-2.18%)
Dodge & Cox 6,069 sh (-6.18%)
Mario Gabelli 191,450 sh (-7.85%)
James Barrow 7,571,176 sh (-12.45%)
John Rogers 104,630 sh (-36.38%)
Chuck Royce 3,000 sh (-94.2%)
» More
Q4 2013

WAG Guru Trades in Q4 2013

Andreas Halvorsen 11,604,944 sh (New)
John Keeley 3,682 sh (New)
Steven Cohen 335,584 sh (+357.89%)
RS Investment Management 52,100 sh (+5.68%)
George Soros 515,700 sh (+3.14%)
First Pacific Advisors 2,295,200 sh (+0.29%)
Pioneer Investments 2,325,918 sh (+0.06%)
Steven Romick 2,175,000 sh (unchged)
Eric Mindich 1,000,000 sh (unchged)
Dodge & Cox 6,069 sh (unchged)
John Rogers Sold Out
Louis Moore Bacon Sold Out
Chuck Royce Sold Out
Tom Gayner 2,147,450 sh (-0.08%)
Ken Fisher 5,737 sh (-0.31%)
John Buckingham 150,884 sh (-0.95%)
Mario Gabelli 188,750 sh (-1.41%)
Jeremy Grantham 3,555,906 sh (-2.31%)
Jim Simons 1,387,600 sh (-4.42%)
James Barrow 6,972,657 sh (-7.91%)
Vanguard Health Care Fund 10,913,200 sh (-12.46%)
Bill Frels 14,013 sh (-16.53%)
Larry Robbins 5,951,526 sh (-20.04%)
Manning & Napier Advisors, Inc 70,004 sh (-28.29%)
John Hussman 150,000 sh (-49.41%)
Paul Tudor Jones 14,008 sh (-85.99%)
» More
Q1 2014

WAG Guru Trades in Q1 2014

Steven Romick 2,175,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with WAG

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Hussman 2013-12-31 Reduce -49.41%0.43%$54.86 - $60.59 $ 66.7515%150000
Vanguard Health Care Fund 2013-12-31 Reduce -12.46%0.29%$54.86 - $60.59 $ 66.7515%10913200
John Keeley 2013-12-31 New Buy$54.86 - $60.59 $ 66.7515%3682
George Soros 2013-09-30 New Buy0.29%$44.12 - $56.23 $ 66.7533%500000
John Hussman 2013-09-30 Add 46.42%0.28%$44.12 - $56.23 $ 66.7533%296500
Joel Greenblatt 2013-09-30 Sold Out 0.02%$44.12 - $56.23 $ 66.7533%0
John Hussman 2013-06-30 Reduce -62.36%0.59%$44.2 - $50.9 $ 66.7537%202500
James Barrow 2013-06-30 Reduce -16.3%0.15%$44.2 - $50.9 $ 66.7537%8648163
Vanguard Health Care Fund 2013-06-30 Add 6.82%0.13%$44.2 - $50.9 $ 66.7537%12465900
Joel Greenblatt 2013-06-30 New Buy0.02%$44.2 - $50.9 $ 66.7537%10268
John Hussman 2013-03-31 Reduce -69.31%1.18%$37.01 - $47.68 $ 66.7562%538000
Vanguard Health Care Fund 2013-03-31 Add 7.61%0.16%$37.01 - $47.68 $ 66.7562%11670400
George Soros 2013-03-31 Sold Out 0.08%$37.01 - $47.68 $ 66.7562%0
Ray Dalio 2013-03-31 Sold Out 0.06%$37.01 - $47.68 $ 66.7562%0
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Walgreen Company

Weekly Top Insider Buys: Walgreen Company, Alcoa Inc., VeriFone Systems Inc., Brietburn Energy Partners and Investors Real Estate Trust
According to GuruFocus Insider Data, these are the largest insider buys during the past week: Walgreen Company (WAG), Alcoa Inc. (AA), VeriFone Systems Inc. (PAY), Breitburn Energy Partners LP (BBEP) and Investors Real Estate Trust (IRET). Read more...
Top 3 Insider Buys of the Week
The following companies represent the three largest insider buys (in terms of transaction amount and total amount of insiders buying) that occurred over the past week. Read more...
Insider Buys at 52-Week Highs
Several companies have reported group insider buying or pricey singular insider buying as their companies near or hit their 52-week highs. The following three companies have reported these insider buys throughout the month of July. Watching group insider buying (especially at high prices) is important because it can signify a collective faith in the stability and potential for additional growth in a company. It can also be beneficial to note insider buys with large transaction amounts because insiders typically will not invest their money into a company if they know they are going to lose it. [b] Read more...
Guru Favorites Report Insider Transactions
This past week, several large corporations reported their corporate executives and directors making rather large transactions within their companies. All of the companies are at (or are nearing) a 10-year high in prices. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 23.30
WAG's P/E(ttm) is ranked higher than
56% of the 432 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 18.70 vs. WAG: 23.30 )
WAG' s 10-Year P/E(ttm) Range
Min: 10.2   Max: 31.95
Current: 23.3

10.2
31.95
P/B 3.00
WAG's P/B is ranked lower than
51% of the 471 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.70 vs. WAG: 3.00 )
WAG' s 10-Year P/B Range
Min: 1.6   Max: 5.58
Current: 3

1.6
5.58
P/S 0.86
WAG's P/S is ranked lower than
61% of the 490 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.46 vs. WAG: 0.86 )
WAG' s 10-Year P/S Range
Min: 0.36   Max: 1.2
Current: 0.86

0.36
1.2
PFCF 25.10
WAG's PFCF is ranked higher than
60% of the 298 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 21.50 vs. WAG: 25.10 )
WAG' s 10-Year PFCF Range
Min: 9.86   Max: 368.77
Current: 25.1

9.86
368.77
EV-to-EBIT 15.60
WAG's EV-to-EBIT is ranked higher than
54% of the 457 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 13.48 vs. WAG: 15.60 )
WAG' s 10-Year EV-to-EBIT Range
Min: 6.3   Max: 19.9
Current: 15.6

6.3
19.9
PEG 3.40
WAG's PEG is ranked higher than
56% of the 240 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.29 vs. WAG: 3.40 )
WAG' s 10-Year PEG Range
Min: 0.69   Max: 3.66
Current: 3.4

0.69
3.66
Shiller P/E 25.90
WAG's Shiller P/E is ranked higher than
57% of the 236 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 20.14 vs. WAG: 25.90 )
WAG' s 10-Year Shiller P/E Range
Min: 12.14   Max: 42.41
Current: 25.9

12.14
42.41

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.83
WAG's Dividend Yield is ranked higher than
56% of the 408 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.88 vs. WAG: 1.83 )
WAG' s 10-Year Dividend Yield Range
Min: 0.44   Max: 3.11
Current: 1.83

0.44
3.11
Dividend Payout 0.43
WAG's Dividend Payout is ranked higher than
58% of the 361 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.33 vs. WAG: 0.43 )
WAG' s 10-Year Dividend Payout Range
Min: 0.1   Max: 0.7
Current: 0.43

0.1
0.7
Dividend growth (3y) 24.70
WAG's Dividend growth (3y) is ranked higher than
94% of the 231 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 5.90 vs. WAG: 24.70 )
WAG' s 10-Year Dividend growth (3y) Range
Min: 3.7   Max: 26
Current: 24.7

3.7
26
Yield on cost (5-Year) 5.49
WAG's Yield on cost (5-Year) is ranked higher than
89% of the 415 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.10 vs. WAG: 5.49 )
WAG' s 10-Year Yield on cost (5-Year) Range
Min: 1.34   Max: 9.49
Current: 5.49

1.34
9.49
Share Buyback Rate 1.10
WAG's Share Buyback Rate is ranked higher than
88% of the 271 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.10 vs. WAG: 1.10 )
WAG' s 10-Year Share Buyback Rate Range
Min: 3.9   Max: -1
Current: 1.1

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 3.50
WAG's Price/Tangible Book is ranked lower than
55% of the 414 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.10 vs. WAG: 3.50 )
WAG' s 10-Year Price/Tangible Book Range
Min: 1.94   Max: 10.32
Current: 3.5

1.94
10.32
Price/DCF (Projected) 1.50
WAG's Price/DCF (Projected) is ranked higher than
65% of the 240 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.30 vs. WAG: 1.50 )
WAG' s 10-Year Price/DCF (Projected) Range
Min: 0.73   Max: 18.65
Current: 1.5

0.73
18.65
Price/Median PS Value 1.30
WAG's Price/Median PS Value is ranked lower than
57% of the 460 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.10 vs. WAG: 1.30 )
WAG' s 10-Year Price/Median PS Value Range
Min: 0.57   Max: 3.19
Current: 1.3

0.57
3.19
Price/Peter Lynch Fair Value 3.60
WAG's Price/Peter Lynch Fair Value is ranked lower than
70% of the 141 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.30 vs. WAG: 3.60 )
WAG' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.8   Max: 3.62
Current: 3.6

0.8
3.62
Price/Graham Number 1.90
WAG's Price/Graham Number is ranked lower than
51% of the 380 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.40 vs. WAG: 1.90 )
WAG' s 10-Year Price/Graham Number Range
Min: 0.99   Max: 5.06
Current: 1.9

0.99
5.06
Earnings Yield (Greenblatt) 6.40
WAG's Earnings Yield (Greenblatt) is ranked higher than
60% of the 467 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 7.40 vs. WAG: 6.40 )
WAG' s 10-Year Earnings Yield (Greenblatt) Range
Min: 5   Max: 15.9
Current: 6.4

5
15.9
Forward Rate of Return (Yacktman) 9.91
WAG's Forward Rate of Return (Yacktman) is ranked higher than
77% of the 279 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 9.93 vs. WAG: 9.91 )
WAG' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 10.4   Max: 17.8
Current: 9.91

10.4
17.8

Business Description

Industry: Retail - Defensive » Pharmaceutical Retailers
Compare:SHDMF, APNHF, GNC, JCOUF, PMC » details
Traded in other countries:WGN.Germany
Walgreen Company was incorporated in the state of Illinois in 1909 as a successor to a business founded in 1901. Its corporate strategy is to provide convenient access to healthcare services and consumer goods in America through its 7,930 community based drugstores, as well as through its specialty pharmacy, home infusion, worksite health center and retail clinic businesses. The Company's drugstores are engaged in the retail sale of prescription and non-prescription drugs and general merchandise. General merchandise includes, among other things, household items, personal care, convenience foods, beauty care, photofinishing, candy, and seasonal items. Walgreens offers customers the choice to have prescriptions filled at the drugstore counter, as well as through the mail, by telephone and via the Internet. Inventories are purchased from numerous domestic and foreign suppliers. The business is seasonal in nature, with Christmas generating a higher proportion of front-end sales and earnings than other periods. Both prescription and non-prescription drug sales are affected by the timing and severity of the cold/flu season. The Company generally finances its inventory and expansion needs with internally generated funds. It sells to numerous customers including managed care organizations. Walgreens competes with different retailers, including chain and independent drugstores, mail order prescription providers, grocery stores, convenient stores, mass merchants and dollar stores. Its retail drugstore, pharmacy benefit and health services businesses are subject to numerous federal, state and local regulations.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide